Hosted on MSN6d
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses ExpectationsBiopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q4 CY2024, with sales up 7.5% year on year to $12.34 ...
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb BMY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
Bristol Myers expands cost-cutting program by $2 billion Drugmaker sees loss of exclusivity of some cancer drugs in 2025 Posts better-than-expected fourth-quarter earnings Feb 6 (Reuters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback